<DOC>
	<DOCNO>NCT01269801</DOCNO>
	<brief_summary>The purpose study see well Juvederm Ultra XC Juvederm Ultra Plus XC , BOTOX Cosmetic , work compare use together cosmetic treatment age-associated wrinkle fold face .</brief_summary>
	<brief_title>Study BOTOX JUVEDERM Treatment Moderate Severe Facial Wrinkles Folds</brief_title>
	<detailed_description>1 . Compounds : 1 . BOTOX Cosmetic ( onabotulinumtoxinA ) Injection 2 . JUVEDERM Ultra XC JUVEDERM Ultra Plus XC Injectable Gel 2 . The objective study : 1 . To assess physician assessment efficacy incremental benefit follow BOTOX Cosmetic Juvederm treatment moderate severe facial wrinkle fold ; 2 . To assess patient perception treatment outcomes incremental benefit follow BOTOX Cosmetic Juvederm treatment moderate severe facial wrinkle fold . 3 . Investigator study site : 1. multicenter study 2 . 5 Sites : 2 US , 2 Canada , 1 EU</detailed_description>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Adult female male , age 25 65 year ; Subjects must seek treatment either BOTOX® JUVÉDERM injection ; Subjects must one moderate severe hyperfunctional facial line upper face ( i.e. , glabellar line , lateral canthal line ( crow 's foot ) horizontal forehead line ) moderate severe nasolabial fold base physician observer assessment ( 03 scale ) ; Women must either nonchildbearing potential ( i.e. , surgically sterilize postmenopausal ) childbearing potential , must pregnant ( document negative urine pregnancy test baseline examination ) lactating must practice medically acceptable method birth control ; Subjects must willing able provide write informed consent ; Subjects must willing able follow procedure outline protocol . Female subject pregnant ( positive urine pregnancy test ) infant breastfeed childbearing potential practicing reliable method birth control ; Previous botulinum toxin semipermanent injectable filler therapy within past year prior history permanent filler therapy injection ; Prior cosmetic procedure ( i.e. , liposuction , etc . ) visible scar may affect evaluation response and/or quality photography ; Known allergy sensitivity study medication component ; Known severe allergy manifest history anaphylaxis history presence multiple severe allergy ; Diagnosis myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis disease might interfere neuromuscular function ; Concurrent use aminoglycoside antibiotic interfere neuromuscular function ; Subjects profound atrophy excessive weakness muscle target area ( ) BOTOX injection ; Subjects infection injection site systemic infection ( case , postpone study entry one week follow recovery ) ; Concurrent participation investigational drug device study participation within 30 day study start ; Subjects undergo additional cosmetic procedure study period ; Subjects change use facial product 6 month prior enrollment study period ; Subjects history poor cooperation , noncompliance medical treatment , unreliability .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>BOTOX</keyword>
	<keyword>JUVEDERM</keyword>
	<keyword>Prospective</keyword>
	<keyword>Open Label</keyword>
	<keyword>Randomized</keyword>
	<keyword>Crossover Study</keyword>
</DOC>